Adam Stern

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy thing to do. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com. Our Mission: We make it easy for people to care for their health, with continuous and connected support that anticipates needs, understands motivation, and simplifies behavior change to put better health and outcomes in everyone’s reach. Investors, please visit Investors, please visit: https://dariohealth.investorroom.com/Welcome

Aerami Therapeutics is breathing life into the treatment of serious and rare cardiopulmonary conditions with a mission-driven objective: develop products that help patients live longer and help them live better. We do this by combining precision medicines and advanced administration platforms that support ease-of-use and quality-of-life. Our lead program, AER-901 (inhaled imatinib) in pulmonary hypertension, has been intentionally designed to potentially reverse the damage caused by disease progression while overcoming many of the limitations of oral, parenteral, and other inhaled delivery technologies. To learn more, visit: https://aerami.com/ #Aerami #Cardiopulmonary #PulmonaryHypertension #PulmonaryArterialHypertension #PH #PAH #ILD #HeartDisease #LungDisease #InhaledTherapeutics #AER901 #AER601

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.

We are pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic key aspects of human biology and disease. We intend to fundamentally alter the drug discovery landscape by the development of novel therapies for disease which have a much higher chance of efficacy in the clinic focused on human primary cell 3D models of disease that more faithfully recapitulate disease processes. Learn more at www.organovo.com.

About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com. About the Neuro-Spinal Scaffold™ Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

At OPKO Health, we seek to serve unmet patient needs through our first in class products, comprehensive diagnostics laboratories, robust research and development pipeline, and unique pharmaceutical business solutions. The entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs. We are proud of our first in class products, Rayaldee® (calcifediol), and the 4Kscore® test, as well as our diagnostics division, BioReference Laboratories and GeneDx. In addition to our clinical products and diagnostics, we have a robust research and development pipeline and a variety of biomedical and pharmaceutical business solutions. Since our founding in 2007, OPKO has grown into a global healthcare company, with over 5500 employees spanning nine countries, through organic growth and complementary acquisitions. More information available at www.opko.com.

ThinkEquity is a boutique investment bank created by experienced professionals that have worked together for over a decade, collectively financing over $50 billion of public and private capital raises, restructurings, and mergers and acquisitions. The ThinkEquity model is built around the clients’ needs, no matter how complicated or around the clock attention required, and to identify solutions that help them to create value for their investors.

Western Acquisition Ventures Corp. is a blank check company, also known as a special purpose acquisition company or SPAC, formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar initial business combination with one or more businesses or entities. Our management team, board of directors, advisors and underwriters have deep knowledge across multiple business sectors and a proven track record in SPACs, M&A and operations. We seek to leverage and capitalize on our collective multi-faceted expertise and broad network of relationships to source and evaluate potential transactions and create value for our stakeholders. Underwritten by leading investment bank’s: Alliance Global Partners, The Benchmark Company and Brookline Capital Markets, Western Acquisition Ventures Corp further extends its access to proprietary deal flow, relationships, industry knowhow and experience to successfully complete a business combination with a high growth industry target.

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy thing to do. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com. Our Mission: We make it easy for people to care for their health, with continuous and connected support that anticipates needs, understands motivation, and simplifies behavior change to put better health and outcomes in everyone’s reach. Investors, please visit Investors, please visit: https://dariohealth.investorroom.com/Welcome

Aerami Therapeutics is breathing life into the treatment of serious and rare cardiopulmonary conditions with a mission-driven objective: develop products that help patients live longer and help them live better. We do this by combining precision medicines and advanced administration platforms that support ease-of-use and quality-of-life. Our lead program, AER-901 (inhaled imatinib) in pulmonary hypertension, has been intentionally designed to potentially reverse the damage caused by disease progression while overcoming many of the limitations of oral, parenteral, and other inhaled delivery technologies. To learn more, visit: https://aerami.com/ #Aerami #Cardiopulmonary #PulmonaryHypertension #PulmonaryArterialHypertension #PH #PAH #ILD #HeartDisease #LungDisease #InhaledTherapeutics #AER901 #AER601

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.